Formoterol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Formoterol: From Long-Acting Bronchodilator Therapy to Obstructive Lung Disease (COPD)
One-Sentence Summary
Formoterol is a long-acting beta2-adrenergic agonist (LABA) bronchodilator already used worldwide in asthma and COPD combination inhalers, though no formal original-indication record was returned for this jurisdiction in the evidence pack. Among the ten TxGNN-predicted indications reviewed, Obstructive Lung Disease (COPD) carries by far the strongest supporting evidence, with 50 clinical trials and 20 publications identified, including multiple landmark Phase 3 mortality/exacerbation trials (ETHOS, KRONOS, FULFIL). Note: TxGNN’s single highest-scoring raw prediction, “respiratory malformation,” was reviewed and excluded from this report — the evidence pack’s own analysis flags it as a knowledge-graph node-matching artefact, since the underlying trials and literature are entirely about asthma/COPD, not structural airway malformation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack (Data Gap); formoterol is a well-established LABA bronchodilator for asthma/COPD based on the trial and literature evidence contained in this pack |
| Predicted New Indication | Obstructive Lung Disease (COPD) |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L1 |
| Australia Market Status | Not Marketed (0 ARTG entries recorded) |
| Number of ARTG Entries | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not returned from the source query for this evidence pack (Data Gap). Based on the extensive trial and literature evidence it does contain, formoterol is a long-acting beta2-adrenergic agonist (LABA) that activates β2 receptors on airway smooth muscle, raising cAMP/PKA signalling to produce rapid-onset, long-duration (12+ hour) bronchodilation. It is a core component of numerous fixed-dose combination inhalers (e.g., budesonide/formoterol, beclometasone/formoterol, glycopyrronium/formoterol, aclidinium/formoterol) used globally in obstructive airway disease.
Obstructive Lung Disease (a category that principally captures COPD) shares the same underlying pathophysiology that formoterol’s LABA mechanism directly targets — airflow limitation from bronchial smooth-muscle tone and airway remodelling. This is reflected in landmark completed Phase 3 trials such as ETHOS, KRONOS and FULFIL, which evaluated formoterol-containing triple/dual therapies against hard clinical endpoints (FEV1, exacerbation rate, and — notably in ETHOS — all-cause mortality).
By contrast, the model’s single top-ranked raw output, “respiratory malformation,” has no mechanistic plausibility: it is a structural congenital anomaly, not a functional airway-tone disorder, and every trial/publication returned for it is actually about asthma, COPD or Symbicort — confirming this is very likely an ontology-adjacency artefact in the knowledge graph rather than a genuine signal. The other TxGNN-ranked candidates with no supporting trials or literature (Rienhoff syndrome, interstitial emphysema, hyperlucent lung, compensatory emphysema, asthma-related genetic susceptibility) are model-score-only predictions with no clinical or mechanistic basis and are not carried forward in this report.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT06744374 | N/A (observational) | Completed | 22,369 | Real-world mortality/cardiopulmonary event comparison, single-inhaler (BGF) vs multiple-inhaler triple therapy in COPD |
| NCT00206154 | Phase 3 | Completed | 1,500 | Symbicort pMDI vs formoterol, budesonide, combination and placebo in COPD maintenance |
| NCT07069829 | N/A (observational) | Recruiting | 1,400 | Real-world clinical/patient-reported outcomes, Breztri/Trixeo triple therapy in moderate-severe COPD |
| NCT00793624 | Phase 3 | Completed | 906 | 48-week long-term efficacy/safety of once-daily BI 1744 CL vs twice-daily Foradil (formoterol) in COPD |
| NCT03662711 | Phase 4 | Terminated | 843 | 1-year LABD ± ICS effect on re-hospitalisation/death in elderly COPD patients (graded directly relevant) |
| NCT03963167 | N/A (observational) | Completed | 661 | 12-month real-world health status and adherence with Trimbow (BDP/FF/G) in COPD |
| NCT05311306 | N/A (observational) | Completed | 475 | Real-world change in clinical/patient-reported outcomes with TRIXEO (budesonide/glycopyrronium/formoterol) in COPD |
| NCT00421122 | Phase 3 | Completed | 315 | Symbicort Turbuhaler vs Pulmicort Turbuhaler + Bricasol pMDI in Chinese COPD patients |
| NCT00252785 | Phase 3 | Completed | 340 | Symbicort Turbuhaler vs Pulmicort Turbuhaler + Theolong tablet, Japanese patients (graded directly relevant) |
| NCT02347072 | Phase 3 | Completed | 80 | 24-hour lung function profile of PT003 vs Spiriva Respimat vs placebo in moderate-to-very-severe COPD |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33252985 | 2021 | RCT | Am J Respir Crit Care Med | ETHOS trial: budesonide/glycopyrrolate/formoterol reduced all-cause mortality vs dual therapy in COPD |
| 30232048 | 2018 | RCT | Lancet Respir Med | KRONOS trial: triple therapy (BGF) vs dual therapies in moderate-to-very-severe COPD |
| 28375647 | 2017 | RCT | Am J Respir Crit Care Med | FULFIL trial: once-daily triple therapy vs dual ICS/LABA in COPD |
| 39213002 | 2025 | Cohort | Am J Respir Crit Care Med | Post hoc ETHOS analysis: effect of triple therapy on cardiovascular/severe cardiopulmonary events |
| 33273813 | 2020 | Review | Int J Chron Obstruct Pulmon Dis | Overview of formoterol pharmacology and efficacy in COPD |
| 35512458 | 2022 | Analysis | Respir Med | ETHOS sub-analysis: prior ICS use and benefits of BGF on exacerbations, symptoms, QoL and lung function |
| 39420338 | 2024 | RCT | Respir Res | TRIFORCE trial: BDP/FF/G effects on lung hyperinflation and exercise endurance in COPD |
| 40619503 | 2025 | Comparative effectiveness | Adv Ther | FF/UMEC/VI vs BUD/GLY/FORM in COPD patients stepping up from dual therapy |
| 31951778 | 2020 | Review | Expert Rev Clin Pharmacol | Aclidinium bromide/formoterol fumarate for maintenance treatment of COPD |
| 26049917 | 2015 | Review | Eur J Intern Med | Extensive review of long-acting bronchodilators formoterol and salmeterol in COPD |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. No key warnings, contraindications, or drug-interaction data were returned for formoterol in this evidence pack (source query status: not found), and no ARTG-registered Australian product record was located to cross-check against.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 3 RCTs (ETHOS, KRONOS, FULFIL) plus a large real-world evidence base directly support formoterol-containing regimens in obstructive lung disease/COPD, giving this candidate the highest evidence level (L1) and most mature decision stage (S3) of all ten TxGNN outputs reviewed. However, formoterol currently has no ARTG-registered product recorded in this dataset and no TFDA-equivalent safety/warning data was retrievable, so this should be treated as evidence-supported guidance pending local regulatory confirmation rather than a ready-to-implement recommendation.
To proceed, the following is needed:
- Confirmation of current Australian ARTG registration status and product listings for formoterol (0 entries returned here appears to be a data-gap rather than a true absence of marketed product)
- Product Information (PI) warnings, contraindications and drug-interaction data
- Formal mechanism-of-action record from DrugBank/equivalent source
- Clarification of why TxGNN’s top-ranked output (“respiratory malformation”) is a knowledge-graph artefact, to avoid this recurring in automated triage of future candidates
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.